The two companies announced an agreement to add Aiforia’s artificial intelligence technology to Genuv’s ATRIVIEW® proprietary drug discovery platform, used to screen both existing drugs and new substances for neuroprotective and neuroregenerative effects. ATRIVIEW® was used to discover Genuv’s leading drug candidate, SNR1611, which has shown the ability to restore CNS function in preclinical models of amyotrophic lateral sclerosis (ALS) and Alzheimer’s Disease.
ATRIVIEW® AI will seamlessly incorporate Aiforia’s AI software to speed up and automate image analysis, normally a time-consuming step with traditional methodologies, to allow for efficient analysis of multiple biomarkers while minimizing the chance of human error in R&D studies. This marks the first time that Aiforia’s technology is being used for differentiating the stages of stem cell development in the brain; an important application in the preclinical investigation of various neurological disorders.
“Aiforia is helping Genuv bring the power of deep learning artificial intelligence to our unique ATRIVIEW® drug discovery platform,” said Sungho Han, Ph.D., founder and CEO of Genuv. “The additional speed will enable Genuv and our partners to bring more drug candidates to the clinic with greater speed.”
“We’re excited to help Genuv extend the capabilities of the remarkable ATRIVIEW® platform with the help of our powerful deep learning technology that is made for use cases such as this; bringing increased efficiency and precision to medical image analysis in fields like neuroscience,” said Jukka Tapaninen, CEO of Aiforia Technologies Plc. “Genuv is advancing a powerful approach to the enormous unmet need in neurodegenerative diseases and we are humbled to be a part of this collaboration.”